Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Frederick L Locke

Showing results (81-90 of 234) with videos related to

Pageof 24
Sort By:
Leukemia Research|June 11, 2016
Results of a phase II study of lenalidomide and rituximab for refractory/relapsed chronic lymphocytic leukemiaJulio C Chavez, Miguel Piris-Villaespesa, Samir Dalia, et al.
Blood|April 1, 2024
Axicabtagene ciloleucel vs standard of care in second-line large B-cell lymphoma: outcomes by metabolic tumor volumeFrederick L Locke, Olalekan O Oluwole, John Kuruvilla, et al.
Blood|March 18, 2020
Outcomes of older patients in ZUMA-1, a pivotal study of axicabtagene ciloleucel in refractory large B-cell lymphomaSattva S Neelapu, Caron A Jacobson, Olalekan O Oluwole, et al.
Transplantation and Cellular Therapy|March 6, 2023
Outcomes of CD19-Directed Chimeric Antigen Receptor T Cell Therapy for Transformed Nonfollicular LymphomaNing Dong, Lucía Rubio Lopes-Garcia, David Viñal, et al.
Transplantation and Cellular Therapy|November 11, 2023
Chimeric Antigen Receptor T-Cell Therapy in the Outpatient Setting: An Expert Panel Opinion from the American Society for Transplantation and Cellular TherapyOlalekan O Oluwole, Bhagirathbhai Dholaria, Tristan E Knight, et al.
Transplantation and Cellular Therapy|August 15, 2022
Pneumococcal Conjugate Vaccine Does Not Induce Humoral Response When Administrated Within the Six Months After CD19 CAR T-Cell TherapyDasom Lee, Aryanna I Jordan, Meghan A Menges, et al.
Transplantation and Cellular Therapy|November 9, 2025
Recommendations for Defining Chimeric Antigen Receptor T-Cell (CAR T) Dose-Limiting Toxicities (DLTs) for Future Early-Phase CAR T Therapy StudiesFrederick L Locke, Sarah Nikiforow, Matthew J Frigault, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|March 26, 2015
Ofatumumab in combination with glucocorticoids for primary therapy of chronic graft-versus-host disease: phase I trial resultsJoseph Pidala, Jongphil Kim, Brian C Betts, et al.
Frontiers in Oncology|November 12, 2025
Post-progression outcomes following BCMA-directed CAR T-cell therapy in myeloma: impact of extramedullary and paramedullary diseaseZiad Abuhelwa, Fnu Amisha, Wenyi Fan, et al.
American Journal of Cancer Research|July 12, 2021
A phase 1, multicenter study evaluating the safety and efficacy of KITE-585, an autologous anti-BCMA CAR T-cell therapy, in patients with relapsed/refractory multiple myelomaRobert F Cornell, Michael R Bishop, Shaji Kumar, et al.
Pageof 24

Showing results (81-90 of 234) with videos related to

Sort By:
Pageof 24
Leukemia Research|June 11, 2016
Results of a phase II study of lenalidomide and rituximab for refractory/relapsed chronic lymphocytic leukemiaJulio C Chavez, Miguel Piris-Villaespesa, Samir Dalia, et al.
Blood|April 1, 2024
Axicabtagene ciloleucel vs standard of care in second-line large B-cell lymphoma: outcomes by metabolic tumor volumeFrederick L Locke, Olalekan O Oluwole, John Kuruvilla, et al.
Blood|March 18, 2020
Outcomes of older patients in ZUMA-1, a pivotal study of axicabtagene ciloleucel in refractory large B-cell lymphomaSattva S Neelapu, Caron A Jacobson, Olalekan O Oluwole, et al.
Transplantation and Cellular Therapy|March 6, 2023
Outcomes of CD19-Directed Chimeric Antigen Receptor T Cell Therapy for Transformed Nonfollicular LymphomaNing Dong, Lucía Rubio Lopes-Garcia, David Viñal, et al.
Transplantation and Cellular Therapy|November 11, 2023
Chimeric Antigen Receptor T-Cell Therapy in the Outpatient Setting: An Expert Panel Opinion from the American Society for Transplantation and Cellular TherapyOlalekan O Oluwole, Bhagirathbhai Dholaria, Tristan E Knight, et al.
Transplantation and Cellular Therapy|August 15, 2022
Pneumococcal Conjugate Vaccine Does Not Induce Humoral Response When Administrated Within the Six Months After CD19 CAR T-Cell TherapyDasom Lee, Aryanna I Jordan, Meghan A Menges, et al.
Transplantation and Cellular Therapy|November 9, 2025
Recommendations for Defining Chimeric Antigen Receptor T-Cell (CAR T) Dose-Limiting Toxicities (DLTs) for Future Early-Phase CAR T Therapy StudiesFrederick L Locke, Sarah Nikiforow, Matthew J Frigault, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|March 26, 2015
Ofatumumab in combination with glucocorticoids for primary therapy of chronic graft-versus-host disease: phase I trial resultsJoseph Pidala, Jongphil Kim, Brian C Betts, et al.
Frontiers in Oncology|November 12, 2025
Post-progression outcomes following BCMA-directed CAR T-cell therapy in myeloma: impact of extramedullary and paramedullary diseaseZiad Abuhelwa, Fnu Amisha, Wenyi Fan, et al.
American Journal of Cancer Research|July 12, 2021
A phase 1, multicenter study evaluating the safety and efficacy of KITE-585, an autologous anti-BCMA CAR T-cell therapy, in patients with relapsed/refractory multiple myelomaRobert F Cornell, Michael R Bishop, Shaji Kumar, et al.
Pageof 24